Generic Oncology Drugs Market Growth Accelerates: Strategic Forecast Predicts $37.08 Billion by 2029

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Generic Oncology Drugs Industry Market Size Be by 2025?
The market size for generic oncology drugs has experienced significant expansion in the past few years. It's predicted to rise from $27.24 billion in 2024 to reach $28.75 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 5.5%. Factors such as patent expirations, efforts to contain healthcare costs, growing incidence of cancer, health insurance coverage, and the prescribing habits of physicians have contributed to growth during the historic period.

What's the Long-Term Growth Forecast for the Generic Oncology Drugs Market Size Through 2029?
In the coming years, the market size for generic oncology drugs is predicted to witness robust expansion, escalating to " $37.08 billion by 2029 with a compound annual growth rate (CAGR) of 6.6%. The growth anticipated during this forecast period can be associated with approvals of biosimilars, heightening competition, the practice of telemedicine and remote care, customized treatment approaches, and pricing pressures. The forecast period also foresees key trends such as heightened pharmacovigilance, streamlining of regulations, focused combination therapies, precision in generic oncology medications, and increased market accessibility.

View the full report here:
https://www.thebusinessresearchcompany.com/report/generic-oncology-drugs-global-market-report

What Are the Key Growth Drivers Fueling the Generic Oncology Drugs Market Expansion?
The forecasted increase in cancer patients is likely to fuel the expansion of the generic oncology drugs market. Cancer is an uncontrolled cell proliferation impacting various organs, leading to high morbidity and mortality rates worldwide. The accessibility of affordable generic oncology drugs is pivotal in the treatment of cancer as it enhances the reach of critical therapies, encourages market competition, and cuts down healthcare costs. To illustrate, the National Cancer Institute (NCI), a US government body, reported in January 2022 that around 5.4% of the population, or 18.1 million people, in the United States were cancer survivors. Moreover, in 2022, it was found that 623,405 individuals were living with metastatic forms of breast, prostate, lung, colorectal, or bladder cancer, or metastatic melanoma, a number predicted to increase to 693,452 by 2025. Hence, the expected increase in cancer patients is stimulating the expansion of the generic oncology drugs market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12174&type=smp

What Trends Will Shape the Generic Oncology Drugs Market Through 2029 and Beyond?
Innovative formulations are a notable trend escalating in prominence within the generic oncology drugs industry. Firms significantly engaged in the generic oncology drugs market are investing efforts towards the creation of unique drug delivery systems, modified-release formulae, and alternative dosage structures, aimed at elevating patient compliance and reaffirming their marketplace footing. Notably, in January 2023, MSN Laboratories Private Limited, a pharmaceutical company from India specializing in generic drugs, unveiled Palborest - the world's maiden generic Palbociclib tablets designed for advanced breast cancer remediation. This generic breast cancer medication stands out as a cost-friendly alternative to the pioneer tablet, whilst retaining bioequivalence. Its tablet form factor offers a significant benefit over capsules as it can be consumed with or without meals, and in conjunction with proton pump inhibitors or antacids. Moreover, its formulation is devoid of lactose and gelatin, which further bolsters the efficacy of this drug.

How Is the Generic Oncology Drugs Market Segmented?
The generic oncology drugs market covered in this report is segmented -

1) By Molecule Type: Large Molecule, Small Molecule
2) By Route Of Administration: Oral, Parenteral
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, Managed Care Institutions

Subsegments:
1) By Large Molecule: Monoclonal Antibodies, Biologics, Biosimilars
2) By Small Molecule: Chemotherapeutics, Targeted Therapy Agents, Hormonal Therapy Drugs

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=12174&type=smp

Which Companies Are Leading the Charge in Generic Oncology Drugs Market Innovation?
Major companies operating in the generic oncology drugs market include Pfizer Inc., AbbVie, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca Plc, Abbott Laboratories, Fresenius Kabi AG, GlaxoSmithKline PLC, Eli Lilly and Company, Merck & Co. Inc., Baxter International Inc., Mylan N.V., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Cipla Inc., Hikma Pharmaceuticals, Endo Pharmaceuticals Inc., Aspen Pharmacare Holdings Limited, Lupin Limited, Towa Pharmaceutical Co Ltd, Torrent Pharmaceuticals Ltd., Cadila Healthcare Ltd., Accord Healthcare

Which Regions Are Leading the Global Generic Oncology Drugs Market in Revenue?
North America was the largest region in the generic oncology drugs market in 2024. The regions covered in the generic oncology drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12174

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.